UT Health San Antonio Multispecialty and Research Hospital treats first clinical trial participant in novel cancer study
Business Announcement
Updates every hour. Last Updated: 22-Jun-2026 16:16 ET (22-Jun-2026 20:16 GMT/UTC)
The Broad Institute’s Cancer Dependency Map Consortium (DMC) is an academic-industry collaboration that has transformed the study of cancer by developing one of the most comprehensive inventories of tumor vulnerabilities. The next stage of the academic-industrial partnership aims to expand beyond cancer vulnerabilities to investigate cancer resistance, surface targets, and high-dimensional readouts.
Researchers at the Institute for Systems Biology (ISB) reveal a darker side of targeted therapy: the same oncogene inhibition that shuts down cancer growth program can also ignite a stress-driven identity switch — revealing an early escape route that may shape the future of cancer treatment.
An international group have discovered associations between pathogenic variants of the BRCA 1 and 2 genes and four types of cancer. Published in ESMO Open, the findings expand the potential for personalized medicine to several cancer types that currently have limited treatment options and poor prognoses.
Esophageal squamous cell carcinoma (ESCC) is the predominant histological subtype of esophageal cancer, accounting for approximately 90% of cases worldwide, with a particularly high incidence in Asian populations. ESCC is characterized by aggressive behavior and pronounced tumor heterogeneity. Although surgical resection remains the primary curative treatment, patients with locally advanced disease frequently experience recurrence and distant metastasis, resulting in poor clinical outcomes.